Schrodinger Inc (SDGR) Stock Price, Quote & News

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through...

Industry: Health Information Services

Sector: Healthcare

Phone: 212 295 5800

Website: www.schrodinger.com

Address:

1540 Broadway, 24th Floor, New York, United States

scott52 Aug. 1 at 7:30 PM

$SDGR This is an AI stock when the AI sector collapses. When AI rallies, it's a biotech ShitCo. Worst of all worlds.

0 · Reply

Robcat Aug. 1 at 4:36 PM

$SDGR Luckily I jumped in this early morning. Great reversal!

1 · Reply

Rvsty Aug. 1 at 11:48 AM

$SDGR 👀 might see a dip under $19 - great place to load for a swing if we do.

0 · Reply

scott52 Jul. 31 at 2:00 PM

$SDGR I'm tempted to dump my entire position and replace it with long term options. I don't see the point in tying up all this money in a stock that can't move.

2 · Reply

scott52 Jul. 30 at 6:58 PM

$SDGR This is trading like total garbage.

0 · Reply

luckydirb Jul. 29 at 11:10 PM

$SDGR what causes the drop today?

0 · Reply

TalkMarkets Jul. 23 at 9:46 PM

3 Of The 5 Stocks In Our AI-Focused Drug Discovery Portfolio Were Up Significantly Last Week - Here's Why $SDGR $ABCL $RLAY $ABSI $RXRX https://talkmarkets.com/content/stocks--equities/3-of-the-5-stocks-in-our-ai-focused-drug-discovery-portfolio-were-up-significantly-last-week-heres-why?post=511045

0 · Reply

RiverCruiser Jul. 23 at 8:25 PM

$SDGR looks primed

1 · Reply

ramzi77 Jul. 22 at 2:09 PM

$SDGR in target 30

0 · Reply

healthcareguru Jul. 21 at 2:14 PM

$SDGR $ABCL $ABSI short all this trash…just moron retailers begging to learn the hard way. 🐺👎

3 · Reply

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Jul 18, 2025, 10:25 AM EDT - 16 days ago

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Jul 18, 2025, 8:00 AM EDT - 16 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 17, 2025, 8:00 AM EDT - 17 days ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

$Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia$

Jun 27, 2025, 8:00 AM EDT - 5 weeks ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 13, 2025, 1:02 PM EDT - 7 weeks ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Jun 12, 2025, 7:00 AM EDT - 7 weeks ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 6, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Jun 5, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Jun 4, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Jun 3, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Jun 1, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 2 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 29, 2025, 5:00 PM EDT - 2 months ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29, 2025, 8:00 AM EDT - 2 months ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 28, 2025, 12:22 PM EDT - 2 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

May 27, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 26, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 25, 2025, 10:00 AM EDT - 2 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 22, 2025, 12:00 PM EDT - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025, 8:30 AM EDT - 2 months ago

Schrödinger to Present at Jefferies Global Healthcare Conference

May 20, 2025, 11:37 PM EDT - 2 months ago

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

May 20, 2025, 6:30 AM EDT - 2 months ago

Schrödinger Announces CFO Appointment

May 14, 2025, 9:30 AM EDT - 2 months ago

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 7, 2025, 5:59 PM EDT - 3 months ago

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 5, 2025, 8:30 AM EDT - 3 months ago

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Apr 28, 2025, 8:00 AM EDT - 3 months ago

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Apr 23, 2025, 8:30 AM EDT - 3 months ago

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Apr 14, 2025, 8:00 AM EDT - 3 months ago

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Apr 12, 2025, 10:26 AM EDT - 4 months ago

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Mar 10, 2025, 8:30 AM EDT - 5 months ago

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Mar 2, 2025, 1:24 AM EST - 5 months ago

Schrödinger: Still Waiting On A Catalyst

Feb 26, 2025, 7:27 PM EST - 5 months ago

Schrödinger, Inc. (SDGR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 5 months ago

Schrödinger Reports Strong Fourth Quarter and Full-Year 2024 Financial Results

Feb 24, 2025, 8:30 AM EST - 5 months ago

Schrödinger to Participate in Upcoming Investor Conferences

Feb 12, 2025, 8:30 AM EST - 6 months ago

Schrödinger to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26

Jan 13, 2025, 7:00 AM EST - 7 months ago

Schrödinger Provides Update on Progress Across the Business and Outlines 2025 Strategic Priorities

Nov 18, 2024, 8:30 AM EST - 9 months ago

Schrödinger Broadens and Accelerates Predictive Toxicology Initiative

Nov 12, 2024, 10:51 AM EST - 9 months ago

Schrödinger (SDGR) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 6:50 AM EST - 9 months ago

Schrödinger Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 8:30 AM EST - 9 months ago

Schrödinger to Present at Jefferies London Healthcare Conference

Oct 31, 2024, 8:30 AM EDT - 9 months ago

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

scott52 Aug. 1 at 7:30 PM

$SDGR This is an AI stock when the AI sector collapses. When AI rallies, it's a biotech ShitCo. Worst of all worlds.

0 · Reply

Robcat Aug. 1 at 4:36 PM

$SDGR Luckily I jumped in this early morning. Great reversal!

1 · Reply

Rvsty Aug. 1 at 11:48 AM

$SDGR 👀 might see a dip under $19 - great place to load for a swing if we do.

0 · Reply

scott52 Jul. 31 at 2:00 PM

$SDGR I'm tempted to dump my entire position and replace it with long term options. I don't see the point in tying up all this money in a stock that can't move.

2 · Reply

scott52 Jul. 30 at 6:58 PM

$SDGR This is trading like total garbage.

0 · Reply

luckydirb Jul. 29 at 11:10 PM

$SDGR what causes the drop today?

0 · Reply

TalkMarkets Jul. 23 at 9:46 PM

0 · Reply

RiverCruiser Jul. 23 at 8:25 PM

$SDGR looks primed

1 · Reply

ramzi77 Jul. 22 at 2:09 PM

$SDGR in target 30

0 · Reply

healthcareguru Jul. 21 at 2:14 PM

$SDGR $ABCL $ABSI short all this trash…just moron retailers begging to learn the hard way. 🐺👎

3 · Reply

JimmyBluechips Jul. 20 at 10:55 AM

$SDGR is it a shitco “biotech” bottom right runner to the downside? I doubt it. Will it run lower to get everyone in existence out past the 19.30 gap? probably. Idc I’m 90%+ commons now and have allllllllllllllllllllllllll day to wait. How funny is it to watch this? Its not, but this is what it takes for greatness

1 · Reply

OptionsMaster7 Jul. 18 at 4:15 PM

$ABSI $RXRX $SDGR $ABCL $AVXL

1 · Reply

OptionsMaster7 Jul. 18 at 3:33 PM

Tweet From ABSI CEO $ABSI $RXRX $SDGR $ABCL $AVXL

0 · Reply

shrwd Jul. 17 at 10:20 PM

$SDGR today kinda felt like a test of overhead resistance

1 · Reply

shrwd Jul. 17 at 10:15 PM

$SDGR bumped the 200 SMA

0 · Reply

VitaEBella Jul. 17 at 1:19 PM

$SDGR Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target https://ir.schrodinger.com/press-releases/news-details/2025/Ajax-Therapeutics-and-Schrdinger-Expand-Research-Collaboration-to-Include-Additional-JAK-Target/default.aspx

1 · Reply

scott52 Jul. 16 at 9:13 PM

$SDGR This song comes to mind: https://youtu.be/8scSwaKbE64?si=6yqIXq1Fs9p4_f2q

1 · Reply

PaulHartigan553 Jul. 15 at 2:19 AM

$SDGR Watching names return to watchlist

1 · Reply

JarvisFlow Jul. 14 at 1:00 PM

Keybanc has updated their rating for Schrodinger ( $SDGR ) to Overweight with a price target of 30.

2 · Reply

Estimize Jul. 14 at 11:00 AM

Wall St is expecting -0.80 EPS for $SDGR Q2 [Reporting 07/30 AMC] http://www.estimize.com/intro/sdgr?chart=historical&metric_name=eps&utm_c

0 · Reply

Cityhall Jul. 11 at 2:55 PM

$SDGR down again there it goes! Nothing seems to be there to stop it sinking deeper never to resurface again.

1 · Reply

Randall99 Jul. 9 at 12:52 PM

$RVMD becoming an AI play with this partnership with iambic.ai? Similar to $SDGR Crossroads of oncology and tech

0 · Reply

Market Cap	1.43B
Revenue (ttm)	207.54M
Net Income (ttm)	-187.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-90.16%
Debt to Equity Ratio	0.00

Volume	1,118,700
Avg Vol	1,094,342
Day's Range	N/A - N/A
Shares Out	73.38M
Stochastic %K	1%
Beta	1.67
Analysts	Strong Sell
Price Target	$31.22